These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10980175)

  • 21. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ESBL-producing Escherichia coli isolated from children with acute diarrhea - antimicrobial susceptibility, adherence patterns and phylogenetic background.
    Franiczek R; Sobieszczańska B; Turniak M; Kasprzykowska U; Krzyzanowska B; Jermakow K; Mokracka-Latajka G
    Adv Clin Exp Med; 2012; 21(2):187-92. PubMed ID: 23214282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining an extended-spectrum beta-lactamase.
    Livermore DM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM; Mushtaq S; Nguyen T; Warner M
    Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
    Sader HS; Hsiung A; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of beta-lactamases among ampicillin-resistant Escherichia coli and Salmonella isolated from food animals in Denmark.
    Olesen I; Hasman H; Aarestrup FM
    Microb Drug Resist; 2004; 10(4):334-40. PubMed ID: 15650379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
    Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
    J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-spectrum plasmid-mediated beta-lactamases.
    Sirot D
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():19-34. PubMed ID: 8543494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
    Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
    J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
    Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in beta-lactam resistance conferred on Escherichia coli.
    Giakkoupi P; Hujer AM; Miriagou V; Tzelepi E; Bonomo RA; Tzouvelekis LS
    FEMS Microbiol Lett; 2001 Jul; 201(1):37-40. PubMed ID: 11445164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
    Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
    Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases.
    Vimont S; Aubert D; Mazoit JX; Poirel L; Nordmann P
    J Antimicrob Chemother; 2007 Nov; 60(5):1045-50. PubMed ID: 17804425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey.
    Jeong SH; Bae IK; Lee JH; Sohn SG; Kang GH; Jeon GJ; Kim YH; Jeong BC; Lee SH
    J Clin Microbiol; 2004 Jul; 42(7):2902-6. PubMed ID: 15243036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli in Korea.
    Jeong SH; Bae IK; Kwon SB; Lee JH; Jung HI; Song JS; Jeong BC; Kim SJ; Lee SH
    Lett Appl Microbiol; 2004; 39(1):41-7. PubMed ID: 15189286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.